PL3426237T3 - Sposób leczenia zaniku mózgu - Google Patents

Sposób leczenia zaniku mózgu

Info

Publication number
PL3426237T3
PL3426237T3 PL17716067.8T PL17716067T PL3426237T3 PL 3426237 T3 PL3426237 T3 PL 3426237T3 PL 17716067 T PL17716067 T PL 17716067T PL 3426237 T3 PL3426237 T3 PL 3426237T3
Authority
PL
Poland
Prior art keywords
treating brain
brain atrophy
atrophy
treating
brain
Prior art date
Application number
PL17716067.8T
Other languages
English (en)
Inventor
Mattheus Cornelis De Wilde
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Publication of PL3426237T3 publication Critical patent/PL3426237T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17716067.8T 2016-03-08 2017-03-08 Sposób leczenia zaniku mózgu PL3426237T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2016/050160 WO2017155386A1 (en) 2016-03-08 2016-03-08 Method for treating brain atrophy
PCT/NL2017/050141 WO2017155396A1 (en) 2016-03-08 2017-03-08 Method for treating brain atrophy

Publications (1)

Publication Number Publication Date
PL3426237T3 true PL3426237T3 (pl) 2024-04-08

Family

ID=55863158

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17716067.8T PL3426237T3 (pl) 2016-03-08 2017-03-08 Sposób leczenia zaniku mózgu

Country Status (13)

Country Link
US (1) US20190076375A1 (pl)
EP (2) EP3426237B1 (pl)
JP (1) JP6980678B2 (pl)
CN (1) CN109069447A (pl)
AU (1) AU2017231577B2 (pl)
BR (1) BR112018068110A2 (pl)
ES (1) ES2962361T3 (pl)
FI (1) FI3426237T3 (pl)
HR (1) HRP20231115T1 (pl)
PL (1) PL3426237T3 (pl)
PT (1) PT3426237T (pl)
SI (1) SI3426237T1 (pl)
WO (2) WO2017155386A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121055C (en) * 2018-11-30 2024-04-16 Evonik Operations Gmbh Preparation comprising a dispersion of phospholipids and fatty acid salts
JP7506473B2 (ja) 2019-12-20 2024-06-26 ポッカサッポロフード＆ビバレッジ株式会社 アミロイドβ蓄積抑制剤
WO2021167876A1 (en) * 2020-02-21 2021-08-26 Hi Llc Methods and systems for initiating and conducting a customized computer-enabled brain research study
CN117956908A (zh) 2021-09-17 2024-04-30 N·V·努特里奇亚 适合作为营养组合物或补充剂用于患有脑相关障碍、衰退或疾病的动物的固体组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1390378E (pt) * 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
EA200301204A1 (ru) * 2001-04-30 2004-04-29 Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
EP2403501A4 (en) * 2008-12-09 2012-09-19 King Faisal Specialist Hospital & Res Ct PREGNENOLONSULFATE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
WO2013129914A1 (en) * 2012-03-02 2013-09-06 N.V. Nutricia Method for improving functional synaptic connectivity
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
WO2013149384A1 (en) * 2012-04-05 2013-10-10 Nippon Suisan Kaisha, Ltd. Brain atrophy prevention agent
EP2906596B1 (en) * 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
SG10201808984WA (en) * 2014-04-14 2018-11-29 Nutricia Nv Method for assessing and treating or preventing impaired plasma polar lipid levels

Also Published As

Publication number Publication date
JP2019512488A (ja) 2019-05-16
FI3426237T3 (fi) 2023-10-02
EP3426237B1 (en) 2023-08-23
JP6980678B2 (ja) 2021-12-15
BR112018068110A2 (pt) 2019-01-15
SI3426237T1 (sl) 2023-12-29
AU2017231577B2 (en) 2022-04-07
EP3973956A1 (en) 2022-03-30
WO2017155386A1 (en) 2017-09-14
AU2017231577A1 (en) 2018-10-25
ES2962361T3 (es) 2024-03-18
EP3426237A1 (en) 2019-01-16
WO2017155396A1 (en) 2017-09-14
PT3426237T (pt) 2023-11-17
US20190076375A1 (en) 2019-03-14
CN109069447A (zh) 2018-12-21
HRP20231115T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
ZA201706616B (en) Method for treating cancer
EP3500289A4 (en) METHODS OF TREATING TRACHEOBRONCHOMALACIA
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
EP3426612B8 (en) Method for treating waste
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL257691A (en) A method for treating cancer
HK1248133A1 (zh) 治療神經母細胞瘤的方法
HK1251965A1 (zh) 用於治療癲癇的方法
AU2016353600B2 (en) Method for treating mucositis
GB2567616B (en) Treatment method
HK1248135A1 (zh) 用於治療癌症的聯合方法
GB2571601B (en) Treatment method
PL2913284T3 (pl) Sposób oraz urządzenie do obróbki części
PL3426237T3 (pl) Sposób leczenia zaniku mózgu
SG11202001806TA (en) Treatment method
PL3638630T3 (pl) Sposób obróbki szlamu
IL270867A (en) Treatment method
HK1257740A1 (zh) 用於適應的方法
SG10201508795XA (en) Method for treating cancer
HK1257072A1 (zh) 治療多發性硬化的方法
EP3246432A4 (en) Method for treating parts
GB201507268D0 (en) Method for stimulating aerogenosis